Global Dry Powder Inhalers Report 2017: Driven by Research Activity in Powder Formulations

News provided by

Research and Markets

11 Aug, 2017, 17:45 GMT

DUBLIN, August 11, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Dry Powder Inhalers: Products, Therapeutics, Players and Forecasts" report to their offering.

The Dry Powder Inhalers Market Report examines the rising potential of dry powder inhalation. This market is being driven by research activity in powder formulations, advances in particle engineering, and the development of novel device architectures. The combination of improved particle properties and more efficient inhaler designs is creating new opportunities for dry powder inhalation and expanding the range of active compounds that can be effectively delivered to the lung via DPI.

As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient - friendly and cost -effective. Our analysis contained in the dry powder inhalers market report illustrates that inhaled administration in general, and DPI in particular, are well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and the commercialization of therapeutic drugs.

Dry Powder Inhalers: Products, Therapeutics, Markets, Players and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.


Companies Mentioned

  • Abdi Ibrahim
  • Acerus
  • Acorda
  • Actelion
  • Adamis
  • AlgiPharma AS
  • Alkermes
  • Aptar
  • AstraZeneca
  • Baxter
  • Bayer Healthcare
  • Bespak
  • Boehringer Ingelheim
  • Chiesi
  • CoTherix
  • Consort
  • GlaxoSmithKline
  • Hexal
  • Janssen
  • Kamada
  • Mannkind
  • Meda
  • Menarini
  • Merck & Co.
  • Teva
  • Tianjin Kinnovata Pharmaceutial
  • UCB
  • United Therapeutics
  • Vectura
  • Zelos Therapeutics
  • (10+ Others)

Key Topics Covered:

1. Executive Summary

2. Inhaled Drug Therapeutics

3. Dry Powder Technology & Markets

4. DPI Product Assessment & Analysis

5. FDA Approved DPI Products

6. Dual Drug Products

7. EMA Approved DPI Products

8. Dual Drug Products

9. Therapeutic Segment Analysis, Data & Forecasts

10. Market Factors

11. Company Profiles

For more information about this report visit http://www.researchandmarkets.com/research/xrfc3f/dry_powder

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716